Evidence map›Paper›PMID 19460416›Full record

ArticleExperimental hematology2009

In vivo inactivation of MASTL kinase results in thrombocytopenia.

H Jan Johnson, Manish J Gandhi, Ebrahim Shafizadeh, Nathaniel B Langer, Eric L Pierce, Barry H Paw, Diana M Gilligan, Jonathan G Drachman

Abstract read
In one paragraph

Article in Experimental hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Oncogenic Functions of MASTL Kinase.Frontiers in cell and developmental biology · 2018
    Review
  6. Article
  7. Review
  8. Review
  9. The Concise Guide to PHARMACOLOGY 2013/14: enzymes.British journal of pharmacology · 2013
    Article
  10. Review
  11. Article
  12. Article
  13. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

H Jan JohnsonPuget Sound Blood Center, Seattle, Wash. 98104-1256, USA. janj@psbc.org
Manish J Gandhi
Ebrahim Shafizadeh
Nathaniel B Langer
Eric L Pierce
Barry H Paw
Diana M Gilligan
Jonathan G Drachman
Harvard University · USBloodworks Northwest · USBrigham and Women's Hospital · USMayo Clinic in Arizona · USSeagen (United States) · US

Funding

TRANSCRIPTION FACTOR GATA-1 IN TERMINAL ERYTHROID DEVELOPMENTP01HL032262 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1985 to 2021
$38.9M
TRAINING PROGRAM IN MOLECULAR HEMATOLOGYT32HL007623 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI HANDIN, ROBERT I · 1985 to 2010
$7.0M
Frascati: mitochondrial transporter and erythropoiesisR01DK070838 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI PAW, BARRY H · 2007 to 2011
$1.8M
Abnormal Megakaryocyte DevelopmentR01HL074396 · NHLBI · PUGET SOUND BLOOD CENTER · PI GILLIGAN, DIANA · 2003 to 2006
$1.4M
MASTL kinase activity in megakaryocyte differentiationK01DK073136 · NIDDK · BLOODWORKS · PI JOHNSON, HELEN JANETTE · 2006 to 2010
$700k
NHLBI NIH HHS P01 HL032262NHLBI NIH HHS P01-HL032262NHLBI NIH HHS R01 HL074396NHLBI NIH HHS R01-HL074396-04NHLBI NIH HHS T32 HL007623NHLBI NIH HHS T32-HL07623NIDDK NIH HHS K01 DK073136NIDDK NIH HHS K01-DK073136NIDDK NIH HHS R01 DK070838NIDDK NIH HHS R01-DK070838
6 · The paper itself

Abstract

objectiveA missense mutation in the microtubule-associated serine/threonine-like kinase gene (MASTL, FLJ14813) on human chromosome 10 was previously linked to a novel form of autosomal dominant inherited thrombocytopenia in a single pedigree. The mutation results in an amino acid change from glutamic acid at position 167 to aspartic acid and segregates perfectly with thrombocytopenic individuals within this extended family. The phenotype is characterized by mild thrombocytopenia with an average platelet count of 60,000 platelets per microliter of blood. We wanted to determine the expression and localization of MASTL, as well as its role in developing thrombocytes using an in vivo model system. MATERIALS AND

methodsNorthern blot analysis allowed us to examine expression patterns. Morpholino knockdown assays in zebrafish (Danio rerio) were employed to determine in vivo contribution to thrombocyte development. Transient expression in baby hamster kidney cells resulted in localization of both the wild-type and E167D mutant forms of MASTL kinase to the nucleus.

resultsNorthern blot analysis indicates that MASTL messenger RNA is restricted in its expression to hematopoietic and cancer cell lines. A transient knockdown of MASTL in zebrafish results in deficiency of circulating thrombocytes. Transient expression of recombinant MASTL kinase in vitro demonstrates localization to the nucleus.

conclusionsFunctional studies presented here demonstrate a direct relationship between transient knockdown of MASTL kinase gene expression and reduction of circulating thrombocytes in zebrafish. This transient knockdown of MASTL in zebrafish correlates with a decrease in the expression of the thrombopoietin receptor, c-mpl, and the CD41 platelet adhesion protein, GpIIb, but has no effect on essential housekeeping zebrafish gene, EF1alpha.

Indexed as

AnimalsBlood PlateletsCell CountCell LineageEnzyme ActivationGene Expression ProfilingMicrotubule-Associated ProteinsMutation, MissensePlatelet Membrane Glycoprotein IIbProtein Serine-Threonine KinasesReceptors, ThrombopoietinRNA, MessengerThrombocytopeniaZebrafishMAST2 protein, humanMicrotubule-Associated ProteinsPlatelet Membrane Glycoprotein IIbProtein Serine-Threonine KinasesReceptors, ThrombopoietinRNA, Messenger

Identifiers

PMID19460416
PMCPMC2729505
OpenAlexW1987715692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.